Survodutide

"Significant Weight Loss: Clinical trials demonstrated that participants with obesity lost up to 19.5 kg (roughly 19% of body weight) over 46 weeks, with higher doses yielding stronger results.

Liver Health Improvements (MASH/NASH): As a dual agonist, survodutide targets liver fat metabolism via the glucagon receptor, showing high potential in treating metabolic dysfunction-associated steatohepatitis (MASH) by reducing liver fat and fibrosis.

Improved Cardiovascular Risk Factors: Research indicates improvements in blood pressure (both systolic and diastolic) and reduction in LDL-cholesterol and triglyceride levels.

Enhanced Metabolic Control: It reduces HbA1c (blood sugar control) and improves insulin sensitivity.

Reduced Waist Circumference: Participants experienced substantial reductions in waist circumference (up to 16 cm"